...Happy to, Mike. Thanks, and appreciate the opportunity. Really great to be here. So yes, we're really excited about the progress we're making across all the key aspects, functions of the organization today. We're laser-focused as we have been for the last several years in delivering a steady cadence of new really important medicines for patients to drive value for all stakeholders, including, of course, our shareholders. Laser-focused on our 3 near-term commercial opportunities, which will be commercializing ourselves as we move to a fully integrated biotech, which we're just about there now. We're ready for launch. Eplontersen for TTR amyloidosis, Olezarsen for diseases related to severely elevated triglycerides and donidalorsen, our prophylactic treatment for HAE, all going very well, as is our really broad late-stage Phase III pipeline. Today, we have 8 drugs, including those 3 for 10 disease indications, both rare and broad indications, and they're all firing on all cylinders, going...
